Quarterly ResultJul 30, 2026, 07:21 AM
Baxter Q2 Sales $2.96B, EPS $0.26; Raises Full-Year Outlook
AI Summary
Baxter International Inc. reported strong second-quarter 2026 results, with sales reaching $2.96 billion, a 5% increase on both reported and organic bases. The company achieved U.S. GAAP diluted EPS of $0.26 and adjusted diluted EPS of $0.56, exceeding expectations. Following this performance, Baxter raised its full-year 2026 financial outlook for sales and adjusted EPS. Additionally, the Board of Directors declared a quarterly cash dividend of $0.01 per share.
Key Highlights
- Q2 2026 Sales: $2.96 billion, +5% reported and organic.
- Q2 2026 U.S. GAAP Diluted EPS: $0.26.
- Q2 2026 Adjusted Diluted EPS: $0.56.
- Full-year 2026 Reported Sales Growth Outlook: 3% to 4%.
- Full-year 2026 Adjusted EPS Outlook: $1.95 to $2.15.
- Quarterly Cash Dividend: $0.01 per share.
- Medical Products & Therapies Q2 Sales: $2.1 billion, +7% reported.
- Healthcare Systems & Technologies Q2 Sales: $801 million, +4% reported.
Price Impact
More from BAX